TMG to provide PACS consulting to AmeriNet
Technology Marketing Group has signed a three-year contract with AmeriNet to provide the healthcare purchasing organization with research and consulting services in diagnostic imaging and PACS. St. Louis-based AmeriNet represents 14,750 hospitals,
Technology Marketing Group has signed a three-year contract with AmeriNet to provide the healthcare purchasing organization with research and consulting services in diagnostic imaging and PACS.
St. Louis-based AmeriNet represents 14,750 hospitals, medical groups, nursing homes, surgery centers, managed-care organizations, pharmacies, and integrated delivery networks in all 50 states. TMG specializes in technology marketing research, with an emphasis on medical imaging. It has recently begun assisting hospitals with planning for digital image management and PACS projects.
TMG will offer AmeriNet member facilities PACS education seminars, imaging operations assessment programs, benchmark reports comparing imaging centers operations and performance to regional and national data, and development of site-specific quality assurance programs.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
